Baby Madi is the cutest chef ever! Now that will brighten up your day!
Baby Madi is the cutest chef ever! Now that will brighten up your day!
In Germany's industrial heartland, engineering firms have come up with a recipe for surviving the coronavirus pandemic. Keep spending on research and development even if sales drop, build a financial buffer so you can craft a long-term business plan, be flexible with dealers to keep supply chains intact, have an innovative mindset and see crises as opportunities. It's certainly a strategy that is paying off for some of the small and mid-sized "Mittelstand" companies (SMEs) that together provide almost 60% of all jobs in Germany, according to Reuters interviews with six chief executives.
So far, Grover Cleveland has been the only US president to serve two non-consecutive terms
Australia's most populous state said that from Monday it would remove limits on the number of people at weddings, bars and religious services and end a ban on public venue dancing as a run of coronavirus-free days prompted a broad downgrade of social distancing rules. The changes announced by New South Wales (NSW) on Wednesday come in time for Australia's summer holidays and Christmas celebrations, and mark the biggest lifting of precautionary measures since nationwide lockdowns began in March to slow the spread of COVID-19. People in the state, where a third of Australia's 25 million population lives, would also be allowed to drink standing up at pubs, while seated outdoor events could host up to 5,000 people.
The United States could begin sharing sensitive intelligence with Honduras about inbound flights carrying drugs, U.S. officials told Reuters, even as the Central American country faces scrutiny from Washington over drug-related corruption. A proposed memorandum of understanding on intelligence sharing, which has not previously been reported, has yet to be finalized by the U.S. and Honduran governments.
College basketball fans are getting a first glimpse at how loaded this freshman class is with future NBA draft picks. Here's an early assessment of the players and teams that are impressing early this season.
After 86 years, the most difficult works have now been completed in the construction of Belgrade’s St. Stava church, one of the largest Orthodox houses of worship in the world. Removed scaffolding revealed a mosaic spanning 15,000 square metres, constructed with funding from Russia. Motifs dedicated to the first Serbian archbishop are now visible, as well as some unique in the Orthodox world.
Picture grilled chicken with criss-crossed grill marks tossed with sizzling corn and vegetables, but this meat has been grown in a lab. Singapore has given U.S start-up Eat Just the go ahead to sell it's lab-grown chicken. The company says its the world's first regulatory approval for so-called clean meat, without the slaughtering of animals. The chicken is grown from animal muscle cells in a lab. The firm said its meat will be sold as chicken nuggets and that launch details will be coming soon. Though to give this lab-grown chicken a try it may set you back $50 (USD) per nugget. CEO Josh Tetick said the cost could drop to match the price of premium chicken when it first launches in a restaurant in Singapore. Its the latest step in the rise of alternatives to regular meat, popularized by plant-based meat options from companies like Beyond Meat and Impossible Foods... Demand fueled by concerns about health, animal welfare and the environment.
Natural disasters in the past two months caused Vietnam 30 trillion dong ($1.3 billion) in economic damage and killed 192 people, with 57 still missing, authorities said on Wednesday, with its central provinces bearing most of the losses. Vietnam's central region has had a tough year, with its important tourism industry crippled by the coronavirus pandemic long before the arrival of nine typhoons that wiped out crops and damaged homes of hundreds of thousands people. Vietnam's economic growth is expected to slow to 2%-3% this year after expanding 7.02% in 2019 due to the wider impact of the coronavirus pandemic and natural disasters.
The employee was taken to a hospital and diagnosed with a concussion
* Securing a vaccine for all European countries will be a top priority for Portugal when it takes over the presidency of the European Union next January, Portuguese Prime Minister Antonio Costa said. * The U.S. Centers for Disease Control and Prevention will soon shorten the length of self-quarantine recommended to 10 days, or 7 days with a negative test, from the current 14-day period.
Snow showers passed over central Pennsylvania on December 1 as wintry conditions affected the state.Falls of up to five inches were recorded in the state’s west as winter weather advisories were issued for the area by the national weather bureau.Timelapse video posted by the National Weather Service in State College shows snow showers and the occasional ray of sunlight break through over the course of the day. Credit: NWS State College via Storyful
Basel, 2 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved Gavreto™ (pralsetinib) for the treatment of adult and paediatric patients 12 years of age and older with advanced or metastatic rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) who require systemic therapy, or with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). These indications were approved under the FDA’s accelerated approval programme based on data from the phase I/II ARROW study. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials. “We are proud to partner with Blueprint Medicines to bring this important new option to people with certain types of RET-altered thyroid cancer,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “Gavreto is now approved across multiple RET-altered tumour types, underscoring our commitment to advancing personalised healthcare with treatments that target the underlying biology of each person’s cancer.” Approximately 10-20% of people with papillary thyroid cancer (the most common type of thyroid cancer)1 have RET fusion-positive tumours,2 and roughly 90% of people with advanced MTC (a rare form of thyroid cancer) carry RET mutations.3 Biomarker testing for RET fusions and mutations can help identify people who are eligible for treatment with Gavreto. The approvals are based on results from the phase I/II ARROW study, which demonstrated durable clinical activity in people with or without prior therapy and regardless of RET alteration genotypes.4 Treatment with Gavreto led to an overall response rate (ORR) of 60% (95% CI: 46%, 73%) in 55 people with RET-mutant metastatic MTC previously treated with cabozantinib and/or vandetanib, and the median duration of response (DoR) was not reached (95% CI: 15.1 months, not estimable).2 In 29 people with cabozantinib- and vandetanib-naïve RET-mutant advanced MTC who were determined to be not eligible for standard therapies, the ORR was 66% (95% CI: 46%, 82%), and the median DoR was not reached (95% CI: not estimable, not estimable).4 In nine people with RET fusion-positive metastatic thyroid cancer, Gavreto demonstrated an ORR of 89% (95% CI: 52%, 100%), and the median DoR was not reached (95% CI: not estimable, not estimable).4 In ARROW trial patients across RET-altered tumour types, the most common adverse reactions (≥25%) were constipation, increased blood pressure (hypertension), fatigue, musculoskeletal pain and diarrhoea.4 The FDA reviewed and approved the application under its Real-Time Oncology Review (RTOR) pilot programme, which aims to explore a more efficient review process to ensure safe and effective treatments are available to patients as early as possible. In September, the FDA also granted accelerated approval to Gavreto for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. In addition, the FDA granted Breakthrough Therapy Designation to Gavreto for the treatment of RET mutation-positive MTC that requires systemic treatment and for which there are no acceptable alternative treatments and for RET fusion-positive NSCLC that has progressed following platinum-based chemotherapy. Gavreto is a once-daily, oral precision therapy designed to selectively target RET alterations, including fusions and mutations. About the ARROW study5ARROW (NCT03037385) is a phase I/II, open-label, first-in-human study designed to evaluate the safety, tolerability and efficacy of Gavreto, administered orally in people with rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer (MTC), RET fusion-positive thyroid cancer and other RET-altered solid tumours. The trial consists of two parts: a dose escalation portion, which is complete, and an expansion portion in people treated with 400 mg of Gavreto, once-daily. ARROW is being conducted at multiple sites across the United States, European Union and Asia. About RET-altered cancersRET gene alterations, such as fusions and mutations, are key disease drivers in many types of cancer, including NSCLC and several types of thyroid cancers. Approximately 10-20% of people with papillary thyroid cancer (the most common type of thyroid cancer)1 have RET fusion-positive tumours,2 and roughly 90% of people with advanced MTC (a rare form of thyroid cancer) carry RET mutations.3 In NSCLC, RET fusions represent approximately 1-2% of patients.6 Oncogenic RET fusions also are observed at low frequencies in cholangiocarcinoma, colorectal, neuroendocrine, ovarian, pancreatic and thymus cancers. About GavretoGavreto is a once-daily, oral precision therapy designed to selectively target RET alterations, including fusions and mutations, regardless of the tissue of origin. Preclinical data have shown that Gavreto inhibits primary RET fusions and mutations that cause cancer in subsets of patients, as well as secondary RET mutations predicted to drive resistance to treatment. Blueprint Medicines and Roche are co-developing Gavreto for the treatment of patients with various types of RET-altered cancers. Blueprint Medicines and Roche are co-developing Gavreto globally, excluding Greater China.* Blueprint Medicines and Genentech, a wholly owned member of the Roche Group, will co-commercialise Gavreto in the US and Roche has exclusive commercialisation rights for Gavreto outside of the US, excluding Greater China.* About Roche Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI). The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2019 employed about 98,000 people worldwide. In 2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 61.5 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com. * Greater China encompasses Mainland China, Hong Kong, Macau and Taiwan All trademarks used or mentioned in this release are protected by law. References  Cancer Treatment Centers of America. Thyroid Cancer Types [Internet; cited 2020 October]. Available from: https://www.cancercenter.com/cancer-types/thyroid-cancer/types  Santoro M et al. RET Gene Fusions in Malignancies of the Thyroid and Other Tissues. Genes 2020;11(4):424 Li A et al. RET fusions in solid tumours. Cancer Treat Rev. 2019;81:101911 Blueprint Medicines. Data on file. ClinicalTrials.gov. Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW) [Internet; cited 2020 October]. Available from: https://clinicaltrials.gov/ct2/show/NCT03037385  Drilon et al. Targeting RET-Driven Cancers: Lessons From Evolving Preclinical And Clinical Landscapes. Nat Rev Clin Oncol. 2018;15:151‒67. Roche Group Media Relations Phone: +41 61 688 8888 / e-mail: firstname.lastname@example.org Dr. Nicolas Dunant Phone: +41 61 687 05 17 Patrick Barth Phone: +41 61 688 44 86Dr. Daniel Grotzky Phone: +41 61 688 31 10 Karsten Kleine Phone: +41 61 682 28 31Nina Mählitz Phone: +41 79 327 54 74 Nathalie Meetz Phone: +41 61 687 43 05Dr. Barbara von Schnurbein Phone: +41 61 687 89 67 Roche Investor Relations Dr. Karl Mahler Phone: +41 61 68-78503 e-mail: email@example.com Jon Kaspar Bayard Phone: +41 61 68-83894 e-mail: firstname.lastname@example.orgDr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: email@example.com Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: firstname.lastname@example.orgDr. Birgit Masjost Phone: +41 61 68-84814 e-mail: email@example.comDr. Gerard Tobin Phone: +41 61 68-72942 e-mail: firstname.lastname@example.org Investor Relations North America Loren Kalm Phone: +1 650 225 3217 e-mail: email@example.comDr. Lisa Tuomi Phone: +1 650 467 8737 e-mail: firstname.lastname@example.org Attachment 02122020_MR_FDA approval of Gavreto_en
Anew tougher tier system of Covid-19 restrictions for England has come into force, as the national four-week lockdown is lifted. The rules are tougher than in the previous tier system England was face with before its second lockdown began in November.
I'm always comfortable.
'The equals of Klee and Matisse' – the Alabama quilt-makers who shook AmericaThey made quilts to keep the cold at bay. And their bold creations ended up being hailed as masterpieces – the visual equivalent of jazz and blues, tokens of solace and defiance in tragic times
Stonehenge lights up in tribute to Covid's heritage champions. Images of eight people who carried on working on projects amid the pandemic beamed on to stone circle
Terrawatch: what does the inside of a volcano look like?. Detailed analysis of a buried extinct volcano in the Faroe-Shetland Basin reveals some surprises
The government should not impose a faulty definition of antisemitism on universitiesThe IHRA ‘working definition’ is confusing and divisive. Forcing its adoption will not help protect Jewish students and staff • David Feldman is director of the Pears Institute for the Study of Antisemitism at Birkbeck, University of London
RoboDoc: how India’s robots are taking on Covid patient care. The pandemic has spurred on robotics companies building machines to perform tasks in hospitals and other industries
23 days to save Christmas: UK retailers fight Covid gloomCollapse of Debenhams and Arcadia casts shadow as stores hope for festive sales rush * Coronavirus – latest updates * See all our coronavirus coverage